期刊
CANCER CELL
卷 37, 期 4, 页码 514-529出版社
CELL PRESS
DOI: 10.1016/j.ccell.2020.03.010
关键词
-
资金
- MINECO - FEDER funds [SAF2014-60442-JIN]
- Asociacion Espanola contra el Cancer (AECC)
- AEI-MICIU/FEDER [RTI2018-095582-B-I00, RED2018-102723-T]
- iLUNG program from the Comunidad de Madrid [B2017/BMD-3884]
- MINECO [SEV-2015-0510]
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据